Compare Danaher Corporation (DHR) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Vanguard Ultra Short Bond ETF — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while Vanguard Ultra Short Bond ETF trades at $49.68. The key difference: Danaher Corporation pays a 0.8% dividend while Vanguard Ultra Short Bond ETF pays none, and Danaher Corporation is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| DHR | VUSB | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $50.03 |
52-Week Low | $161.91 | $49.60 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Vanguard Ultra-Short Bond ETF (VUSB) trades at $49.64, down slightly by 0.03% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oscillators are neutral. Recent news highlights its role as a cash alternative amid potential Fed rate changes, with a yield around 4.35%. The ETF has declared dividends through mid-2026, providing income stability.
VUSB offers a defensive play with steady dividends, but bearish technicals and interest rate sensitivity pose risks. Its appeal hinges on short-term bond performance and macroeconomic shifts, making it suitable for income-focused investors seeking lower volatility, though limited upside potential exists in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
